Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you're researching tirzepatide with a view to starting treatment, the most useful thing to understand first is this: in the UK, tirzepatide is a prescription-only medicine, which means no shopping route — online or otherwise — bypasses a clinical assessment by a registered prescriber. That said, knowing what to look for, what to avoid, and how legitimate supply actually works will save you time and keep you safe. Tirzepatide is licensed in the UK as Mounjaro, a once-weekly injection made by Eli Lilly, and it has become one of the most searched weight-loss medicines in the country since NICE recommended it for NHS use in December 2024. The decision you're really facing isn't where to buy it, it's how to access it safely, from a pharmacy you can actually verify.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people searching for tirzepatide online are weighing up two questions at once: is this treatment right for me, and can I trust the source I'm considering? The second question tends to be underestimated. Because tirzepatide is a prescription-only medicine under the Human Medicines Regulations 2012, any website offering it without first putting you through a genuine clinical consultation is breaking UK law, full stop. That applies whether the listing looks professional or not.
What that means in practice: the 'shopping' part of finding tirzepatide is less about comparing products and more about comparing providers. The medicine itself (Mounjaro) is the same wherever it originates from the licensed UK supply chain. What differs between providers is whether they're verified, whether their prescribers are qualified, and whether the pen you receive is genuine. The full tirzepatide overview covers what the medicine is and how it works if you'd like that context first.
A useful starting point: any online pharmacy supplying prescription medicines to UK patients must be registered with the General Pharmaceutical Council. You can confirm a pharmacy's registration number directly at the GPhC register, it takes about thirty seconds. If a provider you're considering isn't listed there, walk away. That single check filters out a significant proportion of illegitimate sellers.
The MHRA has issued repeated public warnings about fake weight-loss pens sold through social media channels and unofficial websites. In October 2025 the agency raided the first known illicit UK manufacturing site producing counterfeit tirzepatide pens. Some fake pens seized in earlier operations were found to contain insulin, a potentially life-threatening substitution. The MHRA's Yellow Card scheme exists partly to capture reports of suspect products, and the agency actively investigates tip-offs.
The red flags to watch for when evaluating any supplier are consistent: prices well below the market range without explanation, offers to supply the medicine without any clinical assessment, social-media-only presences with no verifiable pharmacy registration, and discount codes or vouchers attached to prescription medicines. On that last point, legitimate providers do not run promotional codes on POMs. If you see a 'discount code' attached to tirzepatide or any GLP-1 medicine, treat it as a warning sign rather than a saving.
Counterfeit pens aside, there is also the question of clinical safety. Even genuine tirzepatide, started at the wrong dose or in the wrong person, carries real risks. Pancreatitis, significant GI effects, interactions with oral contraceptives, these are reasons the medicine is prescription-only, not bureaucratic inconvenience. Our clinical team reviews every consultation personally before any prescription is issued.
Tirzepatide pricing in the UK shifted substantially from September 2025, when Eli Lilly raised the list price of the higher doses significantly. Typical private prices since then have ranged roughly £149 to £375 per month depending on dose and provider. Those figures are widely reported, but the headline number often omits what a legitimate price should include: the consultation, the prescription, any clinical aftercare, and delivery. A price that looks attractively low sometimes turns out to exclude several of those components, or, in the worst cases, to come from a source that bypasses clinical assessment entirely.
For a detailed breakdown of what private tirzepatide treatment costs in practice, and what a transparent price should cover, the Mounjaro shopping list page goes through the full picture. It's the most honest account of the cost landscape we've been able to put together, and it's worth reading before you commit to any provider. Cheapest is genuinely not the right test for a prescription medicine, what matters is whether the clinical oversight is real and the supply chain is verified.
One practical note: at nume, orders placed before 12pm on a working day are dispatched the same day once clinically approved, arriving with DPD the next working day in plain, unbranded packaging. That structure exists because we know people want this treatment to move quickly, it just has to move safely first. Current treatment pricing is shown on the treatment page rather than in body copy, because prices do shift and we'd rather you see the live figure.
A properly regulated tirzepatide prescription pathway in the UK follows a clear sequence. You complete a clinical consultation, including details about your weight, health conditions, current medicines, and relevant history. A GPhC-registered Independent Prescriber reviews that information personally. For most providers that review happens within a working day; at nume, it happens the same day. Identity and weight are verified before any prescription is issued. If the prescriber considers treatment clinically appropriate, a prescription is generated and dispensed by a GPhC-registered pharmacy sourcing from the licensed UK supply chain.
What this is not: an algorithm signing off answers in seconds, a rubber-stamp process, or a route that works regardless of your health profile. The prescriber can and does decline where the clinical picture warrants it, and repeat orders receive their own clinical review before dispatch. If at any point you want to understand more about your treatment, whether that's about stopping Mounjaro and what that process involves, adjusting expectations, or managing side effects, aftercare should be accessible seven days a week, not limited to a ticketing system. If you are considering stopping tirzepatide and want to know what to expect, that guidance is available as part of the same aftercare provision.
The NHS provides clear patient information on tirzepatide covering side effects, storage and what to do if you miss a dose; it's a reliable reference alongside whatever your prescriber tells you. If you'd like to talk through whether tirzepatide is the right option for your circumstances, our prescribers are the right starting point.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.